Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for FT 218 for the Treatment of Narcolepsy
Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: GlobeNewswire
DUBLIN, Ireland, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), “Avadel” or “the Company,” today announced that FT 218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. FT 218, a once-nightly formulation of sodium oxybate using Avadel’s proprietary Micropump® technology, is currently undergoing testing in a Phase III clinical trial for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. The designation has been granted on the plausible hypothesis that FT 218 may be clinically superior to the same drug already approved for the same indication because FT 218 may be safer due to ramifications associated with the dosing regimen of the previously-approved product. Mike Anderson, Avadel’s Chief Executive Officer, said, “Receipt of Orphan Drug Designation for FT 218 is meaningful for both Avadel and patients suffering from Narcolepsy. N
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near Future [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution [Seeking Alpha]Seeking Alpha
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceGlobeNewswire
AVDL
Earnings
- 11/8/23 - Miss
AVDL
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/15/24 - Form 8-A12B
- 4/15/24 - Form 8-K
- AVDL's page on the SEC website